

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 06/27/2006

APPLICATION NO.	PPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/328,975	C	06/09/1999	JOHN A. WOLFF	MIRUS009	7574
25032	7590	06/27/2006		EXAMINER	
MIRUS CO	_		SCHNIZER, RICHARD A		
505 SOUTH	I ROSA RI)			
MADISON, WI 53719				ART UNIT	PAPER NUMBER
				1635	

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
09/328,975	WOLFF ET AL.	
Examiner	Art Unit	
Richard Schnizer, Ph. D	1635	

	Richard Schnizer, Ph. D	1635							
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence add	ress						
THE REPLY FILED 15 June 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.									
 The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Not a Request for Continued Examination (RCE) in compliant time periods: The period for reply expires 3 months from the mailing date 	wing replies: (1) an amendment, affortice of Appeal (with appeal fee) in one with 37 CFR 1.114. The reply must be of the final rejection.	idavit, or other evider compliance with 37 Cl ust be filed within one	ice, which FR 41.31; or (3) of the following						
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN									
TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL									
2. The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any external a Notice of Appeal has been filed, any reply must be filed AMENDMENTS	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th							
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims.									
NOTE: (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.1 5. Applicant's reply has overcome the following rejection(s) 6. Newly proposed or amended claim(s) would be a non-allowable claim(s).	21. See attached Notice of Non-Co								
 7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed: 8. Claim(s) objected to: 6. Claim(s) rejected: 1,3,5 and 7. Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE 		ll be entered and an e	explanation of						
8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e).									
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appe	al and/or appellant fa	Is to provide a						
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER		•							
 11. The request for reconsideration has been considered by See Continuation Sheet. 12. Note the attached Information Disclosure Statement(s). 	•		nce because:						
13. Other:	(

Continuation of 11. does NOT place the application in condition for allowance because: Applicant argues at page 4 of the response that the amendment to require non-covalent interaction between the nucleic acid and the polycation overcomes the rejection over Degols in view of Leonetti and Weithoff. This is unpersuasive because the claim does not exclude any covalent interaction, it only requires that there must be an ionic interaction. The covalent linkage between the polycation and the oligonucleotide ensures that these oppositely charged entities will be in proximity. One of ordinary skill in the art appreciates that an ionic interaction between polylysine and an oligonucleotide will occur spontaneously in aqueous solution even in the absence of a covalent bond that assures proximity. So, there is no reason to expect that the polylysine moiety of the conjugate of Degols would not form an ionic interaction with the nucleic acid moiety. Applicant also requests reconsideration of the rejection over Wu in view of Degols. Applicant argues that there is no suggestion in Degols that a polyanion can be successfully complexed with a polynucleotide/polycation complex in the absence of a covalent attachment between the polynucleotide and the polycation. This is unpersuasive because there is no reason of record to doubt that such an association can and would occur. Applicant has provided no reason why the presence or absence of a covalent bond between an ionically associated polycation and nucleic acid would affect in any way the further association of that complex with a polyanion. The rejections are maintained.

RICHARD SCHNIZER, PH.D. PRIMARY EXAMINER